FDA Approves Inluriyo / Imlunestran: Oncology Guidance for ESR1-Mutated Breast Cancer Breast Cancer 3 Mins Read Introduction: A New Tool for Breast Cancer Treatment On September 25, 2025, the FDA approved Inluriyo (imlunestrant), an oral selective…
